Concepedia

Publication | Open Access

First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study

DOIFull Paper Access

23

Citations

38

References

2020

Year

Christoph Schliemann, Mirjam Gerwing, Hauke Heinzow, Saliha Harrach, Christian Schwöppe, Moritz Wildgruber, Anna Hansmeier, Linus Angenendt, Andrew F. Berdel, Ursula Stalmann,
Cancers

Abstract

tTF-NGR is safely applicable with this regimen. Imaging showed selective reduction of tumor blood flow and intratumoral hemorrhage and necrosis.

References

YearCitations

Page 1